Ishita Aggarwal, MD
Rheumatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
Offices
1 location · Pacific Rheumatology Associates Medical Group · 3 clinicians in this group
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aggarwal’s office at (415) 923-3060 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A138573 · Current
Licensed to practise in California · since 2015 · expires 2027-05-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$189,681
Medicare paid this office $189,681 for 151 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 114 | $33,732 | $114 |
| Long return visit (40+ min) | 27 | $6,848 | $167 |
| New patient visit (60+ min) | 33 | $6,388 | $194 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $5,897 | $140 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 137 | $5,240 | $14 |
See all 9 services
| Return visit (30+ min) | 114 | $33,732 | $114 |
| Long return visit (40+ min) | 27 | $6,848 | $167 |
| New patient visit (60+ min) | 33 | $6,388 | $194 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $5,897 | $140 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 137 | $5,240 | $14 |
| New patient visit (45+ min) | 23 | $3,063 | $133 |
| Short return visit (20+ min) | 16 | $1,342 | $84 |
| Aspiration and/or injection of fluid from large joint | 13 | $907 | $70 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $57 | None |
Who their Medicare patients are
151 Original Medicare patients in 2024. Average age 75 · Women 66% · Also on Medicaid 10% · Health risk score 1.14. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 61% · Diabetes 30% · Chronic kidney disease 21% · Coronary heart disease 19% · Depression 17% · Cancer 15% · COPD 12% · Atrial fibrillation 11% · Heart failure 8%.
The office billed $371,790, Medicare allowed $244,413 and paid $189,681; for 18,798 services of 26 kinds; $121,456 of it was for drugs given in the office and $68,225 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 151 | 18,798 | 75 | 1.14 | $371,790 | $189,681 |
| 2023 | 127 | 9,540 | 75 | 1.22 | $243,754 | $124,325 |
| 2022 | 124 | 1,586 | 75 | 1.26 | $99,460 | $49,879 |
| 2021 | 107 | 265 | 75 | 1.25 | $43,675 | $25,653 |
| 2020 | 19 | 24 | 77 | 1.69 | $3,290 | $2,071 |
| 2018 | 67 | 122 | 70 | 2.85 | $54,501 | $9,421 |
| 2017 | 41 | 74 | 67 | 2.57 | $31,977 | $5,580 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 92 | $24,929 | $108 |
| New patient visit (60+ min) | 29 | $5,483 | $189 |
| Long return visit (40+ min) | 23 | $5,391 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $3,170 | $65 |
| New patient visit (45+ min) | 14 | $1,967 | $140 |
| Short return visit (20+ min) | 23 | $1,934 | $69 |
| Aspiration and/or injection of fluid from large joint | 11 | $788 | $72 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $65 | None |
2022: 5 services
| Return visit (30+ min) | 87 | $19,840 | $103 |
| New patient visit (60+ min) | 25 | $4,718 | $189 |
| New patient visit (45+ min) | 32 | $4,191 | $131 |
| Short return visit (20+ min) | 21 | $1,859 | $71 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $53 | None |
2021: 4 services
| Return visit (30+ min) | 64 | $14,012 | $106 |
| New patient visit (45+ min) | 33 | $4,941 | $150 |
| Short return visit (20+ min) | 22 | $1,955 | $78 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $832 | $69 |
2020: 1 service
| Return visit (30+ min) | 16 | $1,734 | $102 |
2018: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,596 | $65 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,778 | $94 |
2017: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,526 | $65 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,080 | $98 |
Drugs they prescribed that Part D paid
$1,672,277
Pharmacies billed $1,672,277 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,413) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
1,123 generic and 290 brand-name prescriptions · $1,672,277 in drug cost · 23 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 50 | $441,081 | $8,822 |
| Rinvoq | 35 | $221,411 | $6,326 |
| Humira(Cf) | 23 | $208,302 | $9,057 |
| Orencia Clickject | 31 | $175,448 | $5,660 |
| Enbrel | 14 | $114,638 | $8,188 |
See all 23 drugs
| Enbrel Sureclick | 50 | $441,081 | $8,822 |
| Rinvoq | 35 | $221,411 | $6,326 |
| Humira(Cf) | 23 | $208,302 | $9,057 |
| Orencia Clickject | 31 | $175,448 | $5,660 |
| Enbrel | 14 | $114,638 | $8,188 |
| Humira(Cf) | 16 | $111,672 | $6,980 |
| Xeljanz Xr | 15 | $85,366 | $5,691 |
| Cimzia (2 Pack) | 11 | $63,338 | $5,758 |
| Actemra Actpen | 15 | $51,673 | $3,445 |
| Methotrexate | 318 | $9,837 | $31 |
| Hydroxychloroquine Sulfate | 129 | $5,971 | $46 |
| Febuxostat | 28 | $4,568 | $163 |
| Colchicine | 30 | $3,848 | $128 |
| Leflunomide | 39 | $2,936 | $75 |
| Prednisone | 251 | $1,795 | $7 |
| Sulfasalazine Dr | 35 | $1,086 | $31 |
| Alendronate | 51 | $483 | $9 |
| Allopurinol | 59 | $473 | $8 |
| Gabapentin | 45 | $271 | $6 |
| Folic Acid | 31 | $245 | $8 |
| Amlodipine Besylate | 18 | $60 | $3 |
| Sulfamethoxazole-Trimethoprim | 19 | $58 | $3 |
| Pantoprazole | 19 | $50 | $3 |
Year by year
| 2024 | 1,413 | 173 | 0% (0) | 21% | $1,672,277 |
| 2023 | 1,275 | 155 | None | 21% | $1,732,380 |
| 2022 | 1,150 | 136 | 0% (0) | None | $1,487,531 |
| 2021 | 760 | 94 | None | 25% | $1,026,472 |
| 2020 | 100 | 46 | 0% (0) | 25% | $96,737 |
| 2019 | 56 | 19 | 0% (0) | None | $10,599 |
| 2018 | 73 | 26 | 0% (0) | None | $7,013 |
| 2017 | 71 | 16 | None | 28% | $2,682 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Enbrel Sureclick | 60 | $477,566 | $7,959 |
| Humira(Cf) | 38 | $275,883 | $7,260 |
| Rinvoq | 34 | $272,401 | $8,012 |
| Orencia Clickject | 30 | $177,482 | $5,916 |
| Enbrel | 13 | $98,160 | $7,551 |
| Humira(Cf) | 12 | $83,754 | $6,980 |
| Xeljanz Xr | 12 | $71,458 | $5,955 |
| Xeljanz | 11 | $61,153 | $5,559 |
| Actemra Actpen | 11 | $50,604 | $4,600 |
| Methotrexate | 231 | $8,390 | $36 |
| Hydroxychloroquine Sulfate | 108 | $8,219 | $76 |
| Febuxostat | 23 | $5,665 | $246 |
| Colchicine | 42 | $3,435 | $82 |
| Prednisone | 249 | $2,706 | $11 |
| Leflunomide | 28 | $2,657 | $95 |
| Alendronate | 52 | $1,030 | $20 |
| Allopurinol | 65 | $999 | $15 |
| Sulfasalazine Dr | 17 | $735 | $43 |
| Gabapentin | 39 | $721 | $18 |
| Duloxetine | 16 | $239 | $15 |
| Amlodipine Besylate | 23 | $129 | $6 |
| Cyclobenzaprine | 11 | $75 | $7 |
| Folic Acid | 17 | $68 | $4 |
2022: 24 drugs
| Enbrel Sureclick | 66 | $442,300 | $6,702 |
| Humira(Cf) | 31 | $199,709 | $6,442 |
| Humira(Cf) | 17 | $118,359 | $6,962 |
| Xeljanz Xr | 20 | $106,370 | $5,319 |
| Orencia Clickject | 19 | $105,425 | $5,549 |
| Xeljanz | 19 | $103,182 | $5,431 |
| Enbrel Mini | 13 | $90,680 | $6,975 |
| Rinvoq | 13 | $80,163 | $6,166 |
| Orencia | 11 | $60,570 | $5,506 |
| Actemra Actpen | 11 | $47,741 | $4,340 |
| Hydroxychloroquine Sulfate | 124 | $8,127 | $66 |
| Methotrexate | 188 | $7,448 | $40 |
| Rasuvo | 12 | $6,738 | $561 |
| Febuxostat | 25 | $6,451 | $258 |
| Colchicine | 35 | $5,583 | $160 |
| Prednisone | 277 | $2,669 | $10 |
| Leflunomide | 21 | $2,243 | $107 |
| Mitigare | 12 | $1,220 | $102 |
| Allopurinol | 48 | $837 | $17 |
| Alendronate | 40 | $586 | $15 |
| Celecoxib | 13 | $467 | $36 |
| Gabapentin | 27 | $422 | $16 |
| Folic Acid | 11 | $57 | $5 |
| Sulfamethoxazole-Trimethoprim | 11 | $55 | $5 |
2021: 17 drugs
| Enbrel Sureclick | 42 | $258,623 | $6,158 |
| Humira(Cf) | 24 | $145,169 | $6,049 |
| Xeljanz Xr | 21 | $106,544 | $5,074 |
| Xeljanz | 16 | $92,713 | $5,795 |
| Enbrel Mini | 13 | $82,396 | $6,338 |
| Orencia | 14 | $74,060 | $5,290 |
| Orencia Clickject | 12 | $64,029 | $5,336 |
| Actemra Actpen | 11 | $45,571 | $4,143 |
| Febuxostat | 20 | $7,423 | $371 |
| Hydroxychloroquine Sulfate | 83 | $6,594 | $79 |
| Methotrexate | 130 | $6,212 | $48 |
| Colchicine | 24 | $2,835 | $118 |
| Prednisone | 178 | $1,789 | $10 |
| Leflunomide | 14 | $997 | $71 |
| Allopurinol | 24 | $463 | $19 |
| Alendronate | 33 | $445 | $13 |
| Gabapentin | 19 | $156 | $8 |
2020: 3 drugs
| Hydroxychloroquine Sulfate | 11 | $1,621 | $147 |
| Methotrexate | 20 | $710 | $36 |
| Prednisone | 27 | $497 | $18 |
2019: 1 drug
| Prednisone | 21 | $125 | $6 |
Money from drug and device companies
$1,550 in 2025
| 2025 | 15 | 72 | None | $1,550 |
| 2024 | 19 | 129 | None | $3,005 |
| 2023 | 15 | 107 | None | $2,642 |
| 2022 | 11 | 87 | None | $1,898 |
| 2021 | 11 | 61 | None | $1,130 |
| 2020 | 4 | 18 | None | $345 |
| 2019 | 7 | 9 | None | $171 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $365 | 18 payments
|
| Novartis Pharmaceuticals | Cosentyx | $259 | 20 payments
|
| Amgen | Evenity | $191 | 9 payments
|
| Janssen Biotech | Tremfya | $188 | 5 payments
|
| Ucb | Bimzelx | $156 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $90 | 3 payments
|
See all 72 published payments
| Abbvie | Meals · 2025-12-19 | Rinvoq | $16 |
| Organon | Meals · 2025-12-11 | Hadlima | $24 |
| Amgen | Meals · 2025-12-10 | Enbrel | $20 |
| Amgen | Meals · 2025-12-04 | Tavneos | $26 |
| Janssen Biotech | Meals · 2025-11-26 | Tremfya | $47 |
| Abbvie | Meals · 2025-11-25 | Rinvoq | $26 |
| Radius Health | Meals · 2025-11-22 | Tymlos | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-19 | Cosentyx | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-13 | None | $27 |
| Abbvie | Meals · 2025-11-10 | Rinvoq | $22 |
| Abbvie | Meals · 2025-11-07 | Rinvoq | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-03 | Cosentyx | $7 |
| Abbvie | Meals · 2025-11-01 | Rinvoq | $33 |
| Janssen Biotech | Education · 2025-10-27 | Tremfya | $80 |
| Amgen | Meals · 2025-10-24 | Otezla | $27 |
| Ucb | Meals · 2025-10-23 | Bimzelx | $31 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | Cosentyx | $15 |
| Ucb | Meals · 2025-10-15 | Bimzelx | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Saphnelo | $31 |
| Abbvie | Meals · 2025-10-06 | Skyrizi | $8 |
| Abbvie | Meals · 2025-10-02 | Skyrizi | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | Cosentyx | $10 |
| Abbvie | Meals · 2025-09-23 | Rinvoq | $11 |
| Abbvie | Meals · 2025-09-23 | Rinvoq | $5 |
| Janssen Biotech | Meals · 2025-09-16 | Tremfya | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Cosentyx | $16 |
| Amgen | Meals · 2025-09-09 | Evenity | $32 |
| Novartis Pharmaceuticals | Meals · 2025-09-05 | Cosentyx | $13 |
| Abbvie | Meals · 2025-09-04 | Skyrizi | $23 |
| Pfizer | Meals · 2025-08-29 | Xeljanz | $33 |
| Novartis Pharmaceuticals | Meals · 2025-08-27 | Cosentyx | $19 |
| Abbvie | Meals · 2025-08-20 | Rinvoq | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-19 | Saphnelo | $35 |
| Lilly USA | Meals · 2025-08-15 | Ebglyss | $27 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Cosentyx | $0 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Cosentyx | $3 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Cosentyx | $6 |
| Abbvie | Meals · 2025-08-06 | Skyrizi | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-01 | Cosentyx | $12 |
| Amgen | Meals · 2025-07-28 | Otezla | $11 |
| Abbvie | Meals · 2025-07-25 | Rinvoq | $10 |
| Novartis Pharmaceuticals | Meals · 2025-07-15 | Cosentyx | $14 |
| Abbvie | Meals · 2025-06-28 | Rinvoq | $21 |
| Novartis Pharmaceuticals | Meals · 2025-06-27 | Cosentyx | $13 |
| Amgen | Meals · 2025-05-22 | Evenity | $32 |
| Janssen Biotech | Meals · 2025-03-27 | Tremfya | $21 |
| Abbvie | Meals · 2025-03-22 | Rinvoq | $24 |
| Novartis Pharmaceuticals | Meals · 2025-03-20 | Cosentyx | $14 |
| Amgen | Meals · 2025-03-20 | Evenity | $19 |
| Fresenius Kabi USA | Meals · 2025-03-18 | Adalimumab-Aacf | $26 |
| Ucb | Meals · 2025-03-14 | Bimzelx | $31 |
| Amgen | Education · 2025-03-14 | Tavneos | $8 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Cosentyx | $12 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Cosentyx | $3 |
| Aurinia Pharma U.S. | Meals · 2025-03-12 | Lupkynis | $27 |
| Janssen Biotech | Meals · 2025-03-11 | Tremfya | $20 |
| Novartis Pharmaceuticals | Meals · 2025-03-05 | Cosentyx | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-25 | Saphnelo | $24 |
| Abbvie | Meals · 2025-02-22 | Rinvoq | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-19 | Cosentyx | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-18 | Orencia | $22 |
| Ucb | Meals · 2025-02-12 | Bimzelx | $31 |
| Radius Health | Meals · 2025-02-07 | Tymlos | $27 |
| GlaxoSmithKline | Meals · 2025-02-05 | Benlysta | $17 |
| Amgen | Meals · 2025-02-04 | Otezla | $15 |
| Abbvie | Meals · 2025-01-29 | Rinvoq | $28 |
| Scilex Pharmaceuticals | Meals · 2025-01-24 | Gloperba | $19 |
| Novartis Pharmaceuticals | Meals · 2025-01-22 | Cosentyx | $19 |
| Ucb | Meals · 2025-01-22 | Bimzelx | $30 |
| Pfizer | Meals · 2025-01-14 | Xeljanz | $26 |
| Novartis Pharmaceuticals | Meals · 2025-01-09 | Cosentyx | $19 |
| Abbvie | Meals · 2025-01-09 | Skyrizi | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,005
| Novartis Pharmaceuticals | Cosentyx | $555 | 29 payments
|
| Ucb | Cimzia | $547 | 17 payments
|
| Abbvie | Rinvoq | $510 | 20 payments
|
| Amgen | Tavneos | $433 | 26 payments
|
| Janssen Biotech | Tremfya | $178 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $147 | 5 payments
|
| Biocon Biologics | Hulio | $85 | 3 payments
|
| Genentech USA | Actemra | $82 | 3 payments
|
| Radius Health | Tymlos | $78 | 3 payments
|
| Fresenius Kabi USA | Idacio | $64 | 2 payments
|
| Organon | Renflexis | $61 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $52 | 2 payments
|
| Scilex Pharmaceuticals | Gloperba | $46 | 2 payments
|
| Sobi | Kineret | $38 | 1 payment
|
| Genzyme | Kevzara | $29 | 1 payment
|
| Recordati Rare Diseases Inc. | Sylvant | $27 | 1 payment
|
| Sandoz | Hyrimoz | $27 | 1 payment
|
| Pfizer | Xeljanz | $26 | 1 payment
|
| GlaxoSmithKline | Benlysta | $22 | 1 payment
|
2023: $2,642
| Amgen | Enbrel | $658 | 26 payments
|
| Ucb | Cimzia | $406 | 17 payments
|
| AbbVie | Rinvoq | $373 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $264 | 8 payments
|
| Novartis Pharmaceuticals | Cosentyx | $244 | 12 payments
|
| Janssen Biotech | Tremfya | $162 | 7 payments
|
| Radius Health | Tymlos | $97 | 3 payments
|
| Fresenius Kabi USA | Idacio | $86 | 3 payments
|
| Pfizer | Xeljanz | $85 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $69 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $54 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $48 | 2 payments
|
| Genentech USA | Actemra | $44 | 2 payments
|
| Celltrion USA | Yuflyma | $31 | 1 payment
|
| Lilly USA | Taltz | $23 | 1 payment
|
2022: $1,898
| Abbvie | Rinvoq | $624 | 29 payments
|
| Amgen | Enbrel | $399 | 18 payments
|
| Novartis Pharmaceuticals | Cosentyx | $274 | 15 payments
|
| Ucb | Cimzia | $265 | 12 payments
|
| Aurinia Pharma U.S. | Lupkynis | $84 | 3 payments
|
| Janssen Biotech | Tremfya | $56 | 2 payments
|
| Pfizer | Xeljanz | $53 | 2 payments
|
| Alexion Pharmaceuticals | Strensiq | $50 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $49 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $29 | 1 payment
|
| Genentech USA | Rituxan | $16 | 1 payment
|
2021: $1,130
| AbbVie | Rinvoq | $277 | 12 payments
|
| Novartis Pharmaceuticals | Cosentyx | $207 | 11 payments
|
| Amgen | Enbrel | $184 | 7 payments
|
| Ucb | Cimzia | $168 | 8 payments
|
| Janssen Biotech | Tremfya | $144 | 16 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $42 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $26 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $22 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $17 | 1 payment
|
| Lilly USA | Taltz | $17 | 1 payment
|
2020: $345
| Amgen | Enbrel | $181 | 9 payments
|
| Janssen Biotech | Tremfya | $61 | 3 payments
|
| AbbVie | Humira | $56 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $47 | 3 payments
|
2019: $171
| GlaxoSmithKline | Benlysta | $54 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $28 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $21 | 1 payment
|
| Lilly USA | Taltz | $19 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $18 | 1 payment
|
| Merck Sharp & Dohme | Renflexis | $16 | 1 payment
|
| Celgene | None | $15 | 1 payment
|
Professional record
- NPI
- 1518385699
- Licence
- CA A138573California A138573: Current · expires 2027-05-31
- Trained
- New York University School of Medicine, 2014
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 2100 Webster St Ste 112, San Francisco, CA, 94115
- NPI first listed
- 2014-04-04
- NPI last updated
- 2025-08-29
- NPI record certified
- 2025-08-29
This is when the NPI record was last certified, not a medical board exam.